Treatment
Docetaxel clinical trials
We’re tracking 233 recruiting studies that include Docetaxel, each written for real people, not researchers, below.
Recruiting studies
- NCT06473259Recruiting
Comparing treatments for hormone-sensitive metastatic prostate cancer
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
Orbassano, TorinoAges Any age - NCT06484491Recruiting
Higher-dose proton therapy for stage III lung cancer
This trial tests whether giving a higher dose of a special, precise form of radiation (proton therapy) to the main tumor can improve outcomes for people with stage III lung cancer who are already scheduled for chemoradiation and immunotherapy. It may help by targeting the tumor more effectively while protecting nearby organs.
GroningenAges 18 years+ - NCT06498648RecruitingPhase 1/Phase 2
Abemaciclib with gemcitabine for soft tissue sarcoma
This trial tests whether adding the targeted drug abemaciclib to standard chemotherapy (gemcitabine) works better against certain soft tissue sarcomas. It is for people whose tumors have a normal Rb gene, which may help the drug work.
Houston, TexasAges 18 years+ - NCT06568094RecruitingPhase 1/Phase 2
Study of HRS-5041 with other drugs for advanced prostate cancer
This trial tests a new tablet called HRS-5041 combined with other anti-cancer treatments for men with advanced prostate cancer that has not responded to previous therapies. It aims to see how well the combination works and if it is safe.
Harbin, HeilongjiangAges 18–80 - NCT06592599RecruitingPhase 2
Drug combo for EBV-related nasopharyngeal cancer
This trial tests a combination of three drugs (gemcitabine, docetaxel, and toripalimab) as a first treatment for a type of nasopharyngeal cancer linked to the Epstein-Barr virus. The goal is to see if this combination helps shrink tumors before other treatments like radiation.
Palo Alto, CaliforniaAges 18 years+ - NCT06616584RecruitingPhase 2/Phase 3
Cemiplimab plus standard care for advanced lung cancer after prior treatments
This trial tests whether adding the immunotherapy drug cemiplimab to standard treatment can help people with advanced lung cancer that has already progressed after both platinum chemo and a prior immunotherapy. It is designed for those who responded to their first immunotherapy for at least 12 weeks before the cancer started growing again.
Daphne, AlabamaAges 18 years+ - NCT06629597RecruitingPhase 3
Study of YL201 for advanced nasopharyngeal cancer
This trial tests a new drug, YL201, in people with nasopharyngeal cancer that has come back or spread. It may be an option if you have already tried a PD-(L)1 inhibitor and at least two chemotherapy treatments.
Guangzhou, GuangdongAges 18–75 - NCT06652607Recruiting
PSA response as a sign of treatment success in prostate cancer
This trial is for men with prostate cancer that has spread to other parts of the body and is being treated with hormone therapy. It looks at whether a drop in PSA levels after six months can help predict how well the treatment is working.
Rome, LazioAges 18 years+ - NCT06663137RecruitingPhase 2
Study of a new treatment for high-grade bladder cancer
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
RaananaAges 18–80 - NCT06699212RecruitingPhase 3
Light-activated therapy with immunotherapy for head and neck cancer
This trial tests a new light-activated treatment (ASP-1929) combined with an immunotherapy drug (pembrolizumab) as a first treatment for head and neck cancer that has come back in the same area but has not spread to other parts of the body. It aims to see if this combination works better than standard treatment alone.
Duarte, CaliforniaAges 18 years+ - NCT06704191RecruitingPhase 1/Phase 2
In-home chemo for bladder cancer trial
This trial tests if you can receive chemotherapy for bladder cancer at home instead of in the clinic. It is for people with early-stage bladder cancer who are already getting certain types of intravesical (inside the bladder) treatment.
Jacksonville, FloridaAges 18 years+ - NCT06881784RecruitingPhase 3
Study of a RAS-targeting pill for lung cancer
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
Birmingham, AlabamaAges 18 years+ - NCT06749886RecruitingPhase 2
Tislelizumab plus chemo for advanced lung cancer after prior immunotherapy
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
ShanghaiAges 18 years+ - NCT06769425RecruitingPhase 1
Combination treatment for advanced solid tumors
This trial tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapy. It aims to find a safe dose and see if the combination can shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06793813RecruitingPhase 2
Study of cadonilimab for advanced lung cancer
This trial tests a new drug called cadonilimab for people with advanced non-squamous non-small cell lung cancer that has gotten worse after treatment with immunotherapy and chemotherapy. The goal is to see if it helps control the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06841055RecruitingPhase 2
Pumitamig plus chemo for Stage IV lung cancer after immunotherapy
This trial tests a new investigational drug called Pumitamig (BNT327) given with chemotherapy for people with advanced non-small cell lung cancer (Stage IV) that has continued to grow after one prior treatment with immunotherapy and platinum chemotherapy. The study aims to see if this combination is safe and can help shrink the cancer.
Birmingham, AlabamaAges 18 years+ - NCT06857175RecruitingPhase 3
Comparing a new drug to standard chemo for advanced bladder cancer
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06908304RecruitingPhase 3
Study of THIO + Cemiplimab vs Chemo for Advanced Lung Cancer
This trial tests a new combination of drugs (THIO and cemiplimab) against standard chemotherapy for people with advanced non-small cell lung cancer who have already tried two prior treatments including immunotherapy and platinum chemo. The goal is to see if the combination helps control the cancer better.
PoznanAges 18 years+ - NCT06908993RecruitingPhase 3
Tepotinib vs standard care for MET-mutated lung cancer
This trial tests a targeted pill called tepotinib against standard treatments for advanced lung cancer with a specific MET gene change. It is for people whose cancer has progressed after at least one prior therapy.
BesançonAges 18 years+ - NCT06927180RecruitingPhase 2
Study of SHR-A1811 plus pertuzumab before surgery for HER2+ breast cancer
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
Zhengzhou, HenanAges 18–70 - NCT06940180RecruitingPhase 2
Immunotherapy and chemotherapy before surgery for sinus cancer
This trial tests a combination of an immunotherapy drug (toripalimab) plus chemotherapy before surgery for sinus cancer that has not spread. The goal is to see if this treatment shrinks the tumor so surgery can be more effective.
Boston, MassachusettsAges 18 years+ - NCT06943820RecruitingPhase 1/Phase 2
AK129 combination therapy for advanced solid tumors
This trial tests a new combination of drugs (including AK129) for people with advanced solid tumors, specifically lung cancer, head and neck cancer, or colorectal cancer. It is for those who have already tried a platinum chemo and a PD-1/PD-L1 drug but their cancer got worse.
Shenyang, LiaoningAges 18–75 - NCT06947668Recruiting
Biomarker study for people who can't take cisplatin chemo
This study looks at immune system markers in patients with head and neck cancer who cannot receive the standard chemotherapy drug cisplatin. The goal is to understand how well a different chemotherapy drug (docetaxel) combined with radiation works in these patients.
Erlangen, BavariaAges 18 years+ - NCT06976190RecruitingPhase 3
MRG003 plus pucotenlimab vs chemo for advanced nasopharyngeal cancer
This trial tests whether combining an experimental antibody-drug conjugate (MRG003) with an immunotherapy (pucotenlimab) works better than standard chemotherapy for people with nasopharyngeal cancer that has come back or spread. If you have tried at least one prior treatment and are generally in good health, you may be able to join.
Guangzhou, GuangdongAges 18–75
Common questions
- Are there clinical trials studying Docetaxel?
- Yes. Clin2 currently lists 233 recruiting studies that include Docetaxel, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Docetaxel trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Docetaxel an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Docetaxel or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.